Last month, Dr Om Manchanda, chief executive officer of diagnostics and pathology laboratories firm Dr Lal PathLabs, was in Mumbai to speak at a health care summit. The moment the Gurgaon-based doctor left the venue, an investor from a reputed private equity (PE) fund in South India accosted him and requested for a meeting later in the week. “It’s regarding business,” the investor said by way of explanation. But Dr Manchanda, after scanning his appointment diary, said he only had the time for a quick telephone conversation. The investor agreed, almost as if he couldn’t believe his luck.
There are two things wrong with this tableau. For one, PE players do not usually chase companies, and certainly not at public events. And companies do not walk away when PE firms want to talk “business”. Dr Lal PathLabs, however, has the luxury of brushing aside investors. With 150 laboratories across India that cater to more than 12 million customers every year, the diagnostics firm has already seen its valuation rise by 30 to 40 times over the last decade.
In 2005, Dr Lal PathLabs had only 10 laboratories and revenue of around Rs 45 crore. It was valued at Rs 100 crore in 2007, and investors claim that it will be worth Rs 12,000 crore by 2019-20. The business has been growing at a compound annual growth rate (CAGR) of 25 percent. As of March 2014, its revenues were at Rs 550 crore, and Dr Manchanda expects the company to close FY15 with a turnover of Rs 675 crore.
“What’s worked for Dr Lal PathLabs is that it has a hungry and motivated board of directors and founders backed by an equally motivated and skilled management team,” says Sandeep Singhal, co-founder and managing director of WestBridge Capital Partners, which invested in the diagnostics firm through WestBridge Ventures Fund I first in 2005, and then again in 2007, by which time Westbridge had merged with Sequoia Capital India. (The sum and stake stayed undisclosed on both occasions.)
Since 2007, there has been no primary stake dilution in Dr Lal PathLabs, but there have been two tranches of secondary stake sales (when one PE firm buys out another investor’s stake). Three years ago, Singhal and the co-founders of the original WestBridge team severed ties with Sequoia Capital India, and restarted WestBridge Capital Partners. The founders, however, did not want to lose their investment in Dr Lal PathLabs. In the secondary deal which took place in 2013, WestBridge Capital Partners, along with another PE firm, TA Associates, bought the original stake from the Westbridge fund. The two private equity firms together invested $44 million (about Rs 268 crore) and hold about a 30 percent stake in Dr Lal PathLabs. WestBridge’s contribution was $35 million (about Rs 213 crore) in the deal. In this round, it was valued at between Rs1,500 crore and Rs 1,750 crore.
Now, Dr Lal Pathlabs is preparing for an initial public offering (IPO), to be filed next year, and through which it could raise Rs 400-600 crore. And though WestBridge has been invested in the firm for nine years, it is in no hurry to exit. “We continue to be long-term investors in the company and may stay invested even after the IPO,” says Singhal.
Though the diagnostics firm was founded in Delhi in 1949 by the late Dr (Major) SK Lal—he had trained in the Indian Army and later at Cook County Hospital in Chicago—it was only in 2005 that it started expanding its presence rapidly in India. In doing so, it played an important role in organising the country’s fragmented pathology business. From conducting simple blood tests when it started 65 years ago, it acquired the technology to expand into more complex tests. It was the first private firm in India to conduct thyroid tests in 1999; today it offers a host of diagnostics services in oncology, cardiology, infectious diseases and genetic disorders, to name a few.
(This story appears in the 31 October, 2014 issue of Forbes India. To visit our Archives, click here.)